Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda's Ninlaro Back In European Myeloma Race After CHMP Turnaround

Executive Summary

A CHMP about turn on Takeda's Ninlaro (ixazomib) for multiple myeloma means the Japanese firm is back on track to compensate for lost revenues from the impending patent expiry of key product Velcade. However, the Japanese firm will have a tough time ensuring Ninlaro is not overshadowed by rivals.

You may also be interested in...

Puma's Likely Neratinib EU Knockback May Be Temporary

A positive opinion on the marketing application for Puma's neratinib in the EU is unlikely next month after a recent discussion with regulators failed to satisfy risk-benefit concerns, but more data on controlling diarrhea are expected shortly.

Another Sea Change In Myeloma Promised By New Therapies, Combos

Darzalex made a splash with impressive Phase III data in relapsed multiple myeloma at the EHA and ASCO meetings, but a range of other drugs are on the way, including a next-generation CD38 inhibitor from Sanofi, checkpoint inhibitors and Roche's BCL-2 Venclexta.

Takeda Oncology Hopes Hit By CHMP Ninlaro Rejection; Appeal Planned

An EMA advisory committee has set back Takeda Pharmaceutical Co. Ltd.’s oncology plans by rejecting Ninlaro as a treatment for multiple myeloma in the region, saying supporting data was inadequate for its backing but the Japanese company aims to appeal the decision.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts